Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tevogen Bio Holdings Inc. - Common Stock (NQ:TVGN)

5.190 +0.210 (+4.22%)
Streaming Delayed Price Updated: 10:16 AM EDT, Apr 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tevogen Bio Holdings Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-market trading after reporting fourth-quarter results. Other stocks declining in pre-market trading... 
Via Benzinga
Topics Stocks
News headline image
Tevogen Names Leadership Team to Execute Diversified Growth Strategy
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen CEO Says ‘Actively Evaluating’ Potential Acquisitions ↗
The announcement comes on the heels of the company announcing that it has entered into a letter of intent to evaluate a deal with another pharmaceutical company called Apozel Pharmaceuticals. 
Via Stocktwits
News headline image
Letter to Shareholders from CEO Dr. Ryan Saadi
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Shares Take Further Beating On Gauging Deal With Apozel Pharmaceuticals ↗
If the deal goes through, it could provide Tevogen with an established generics platform, the company said. 
Via Stocktwits
News headline image
Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical
From Tevogen Bio Inc
Via GlobeNewswire
Discover the top movers in Wednesday's pre-market session. ↗
Via Chartmill
News headline image
Tevogen Announces Reverse Stock Split
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
FDA Reversal Sends Atara Biotherapeutics into Tailspin: Stock Plummets 67% on Second CRL for Tabelecleucel
In a stunning blow to the burgeoning field of allogeneic cell therapy, Atara Biotherapeutics (Nasdaq: ATRA) saw its market valuation evaporate this week following a second Complete Response Letter... 
Via MarketMinute
Topics Bankruptcy
News headline image
Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen CEO Donates Shares to Support Education for Underprivileged Children
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen CEO Donates Personal Shares to Support Local Fire Department
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company’s Shares of Common Stock
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest
From Tevogen Bio Inc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.